首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷 CT/MRI/X光

市場調查報告書

商品編碼

1143395

正電子發射斷層掃描 (PET) 全球市場-2022-2029

Global Positron-Emission Tomography (PET) Market - 2022-2029

出版日期: 2022年10月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

在預測期間（2022-2029 年），正電子發射斷層掃描 (PET) 市場規模預計將以 4.78% 的複合年增長率增長。

正電子發射斷層掃描 (PET) 是核醫學中的一種功能成像技術，用於觀察體內的代謝過程，以幫助診斷疾病。與成熟的 PET 相比，PET 具有顯著優勢，例如出色的對比度和分辨率，以及減少的電離輻射。

市場動態

由於放射性藥物對 PET 分析的需求增加、寵物成像技術進步以及各種慢性病發病率上升等因素，PET（正電子發射斷層掃描）市場正在增長。

不斷增長的研發和市場開發正在推動全球市場的增長。

正電子發射斷層掃描 (PET) 可以以高分辨率和靈敏度測量生物系統中的功能過程。生物學和放射化學的最新進展使 PET 可用於研究許多功能過程。此外，研發和市場開發的進步正在推動全球市場的增長。例如，2022 年 7 月 20 日，被譽為創新 PET 放射性藥物開發和商業化領導者的 Bracco, Inc.、Blue Earth Diagnostics, Inc. 宣布，它將有效治療接受雄激素剝奪治療的前列腺癌患者(ADT). 介紹了兩項回顧性研究的結果，該研究評估了 Axumin（Fluciclovine F18）在生化復發男性 PET 成像中的應用，均顯示 Axumin 性能和 ADT 持續時間沒有差異，也影響 Axumin 檢出率，但結果顯示沒有差異。此外，2022 年 7 月 19 日， Radialis 獲得美國 FDA 的批准，可在美國市場銷售器官靶向 PET 設備 Radialis PET Imager。

缺乏適當的報銷政策阻礙了全球市場的增長。

缺乏足夠的報銷政策導致付款人拒絕在全球範圍內對 PET 和 SPECT 程序進行報銷。此外，放射性藥物的半衰期短，使整個過程的成本效益降低，減緩了全球市場的增長。

行業分析

本報告基於波特五力、創新、新產品發布和定價等各種行業因素，對全球正電子發射斷層掃描 (PET) 市場進行了深入分析。

細分分析

在預測期內（2022-2029 年），腫瘤領域預計將主導全球市場。

由於正電子 CT (PET CT) 是一種有效的核成像技術，用於確認各種癌症的存在，腫瘤學領域在 2021 年佔據了市場主導地位。在腫瘤學中，PET（正電子 CT）使用 FDG（18Fluorine-2-Deoxy-d-glucose）作為放射性藥物，以證明與正常細胞相比，惡性細胞的代謝增加。隨著全球癌症患病率的上升，對先進診斷成像技術的需求不斷增加，市場也在不斷擴大。PET和PET/CT檢查佔腫瘤科80%以上，心髒病科和神經科各佔5%左右。此外，世界上癌症發病率的增加增加了腫瘤學領域在全球市場中的主導地位。例如，全球癌症觀察站的統計數據顯示，2020年將有19,292,789例新發各類癌症病例，共有9,958,133人死於不同類型的癌症。因此，對癌症患者的早期診斷和治療的需求增加了 PET 掃描儀的使用，從而導致市場增長。

區域分析

據估計，北美將主導全球 PET（正電子發射斷層掃描）市場。

北美預計將在 2021 年主導正電子發射斷層掃描 (PET) 市場，並在預測期內（2022-2029 年）保持增長，美國癌症患病率上升，PET 掃描數量正在增加，製造商正在引入新設備用於成像。美國每年進行大約 200 萬次 PET 掃描。因為慢性病和癌症病例在美國呈上升趨勢。例如，根據美國國家癌症研究所的數據，2020 年將有超過 1,806,590 例新發癌症和 606,520 例癌症死亡病例。根據美國癌症協會的數據，到 2021 年，將有近 190 萬例新診斷和 608,570 例死亡。而美國疾病控制與預防中心預測，到 2040 年，將有 2950 萬例癌症診斷。此外，Positron Corporation、Segami Corporation、Naviscan Inc、MedX Holdings Inc 和 GE Healthcare 等主要市場份額參與者的存在確保了北美在全球市場的領導地位。

競爭格局

市場上的主要主要參與者有 GE Healthcare、Philips Healthcare、Siemens Healthcare、Positron Corporation、Segami Corporation、Spectrum Dynamics Ltd.、Naviscan Inc.、MedX Holdings Inc.、United Imaging、Neusoft Medical Systems等。主要參與者採取了各種增長戰略，如新產品發布、併購、合作夥伴和聯盟，為全球正電子發射斷層掃描 (PET) 市場的增長做出了貢獻。例如，2022 年 8 月 9 日，GE Healthcare 與 Nex Cubed 合作，為在加拿大推出的 Edison Accelerator 選擇了六家數字健康初創公司。同樣在 2022 年 4 月 1 日，GE Healthcare 將在印度開設一家新的製造工廠。

GE醫療

概述

GE Healthcare 成立於 2004 年，總部位於美國伊利諾伊州芝加哥市。它是美國跨國集團通用電氣的子公司。一家生產和銷售醫療診斷成像設備和放射性藥物的大型公司。

產品介紹

GE Healthcare 的正電子發射斷層掃描 (PET) 產品組合包括 Discovery IQ、Discovery MI Gen 2、MotionFree、NM 830、NM/CT 850、NM/CT 860、NM/CT 870 DR、NM/CT 870 CZT 等。

該報告提供對全球正電子 CT (PET) 市場的大約40 多個市場數據表、45 多個圖表和 200 頁（大約）的訪問。

Market Overview

Positron-Emission Tomography (PET) Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.78% during the forecast period (2022-2029).

Positron-Emission Tomography (PET) is a nuclear medicine functional imaging technique used to observe the metabolic process in the body as an aid to the diagnosis of disease. PET offers significant advantages, including excellent contrast and resolution and reduced ionizing radiation, compared to well-established PET.

Market Dynamics

The positron-emission tomography (PET) market is growing due to several factors, such as rising demand for PET analysis in radiopharmaceuticals, technological advancements in pet imaging, and rising incidence of various chronic diseases.

The growing research and market developments are fueling global market growth.

Positron Emission Tomography (PET) enables a high resolution and high-sensitivity measurement of the biological system's functional processes. The latest advancements in biology and radio-chemistry allowed for the utilization of PET for studying a large number of functional processes. Furthermore, the growing research and market developments are fueling the global market growth; for instance, on July 20, 2022, Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals published the results of two retrospective studies for the evaluation of Axumin (fluciclovine F 18) use for PET imaging in men with biochemical recurrence of prostate cancer who were undergoing androgen deprivation therapy (ADT) and both of which showed that there was no difference in Axumin performance and that the length of time on ADT did not influence Axumin detection rates. Moreover, on July 19, 2022, Radialis Inc. received approval from US FDA to market the Radialis PET Imager, an organ-targeted positron emission tomography (PET) system in the United States market.

The lack of proper reimbursement policies is hampering the global market growth.

Lack of proper reimbursement policies causes rejection of payer's reimbursement for PET and SPECT procedures globally; also, the short half-life of radiopharmaceuticals makes the whole procedure cost ineffective, slowing the global market growth.

Industry Analysis

The global positron-emission tomography (PET) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, Etc.

Segment Analysis

The oncology segment is predicted to dominate the global market during the forecast period (2022-2029).

The oncology segment subjugated the market in 2021, as positron emission tomography (PET CT) is an effective nuclear imaging technique used to confirm the presence of various cancers. In oncology, PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, demonstrating the increased metabolism by malignant cells when compared to that of normal cells. With the rising incidence of cancer globally, the demand for advanced imaging techniques is growing, resulting in market growth. Oncology accounts for more than 80% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 5% each. Furthermore, the growing incidence of cancer globally is driving the dominance of the oncology segment over the global market. For instance, the statistics from the Global Cancer Observatory indicate that in 2020, there were 19,292 789 new cases of all types of cancer, and a total of 9,958,133 deaths were because of different types of cancer. Thus, the need for early diagnosis and treatment of cancer cases has enhanced PET scanners' usage and led to market growth.

Geographical Analysis

North America is estimated to subjugate the global positron-emission tomography (PET) market.

North America dominated the positron-emission tomography (PET) market in 2021 and is expected to maintain the growth over the forecast period (2022-2029), increasing the prevalence of cancer in the United States, rising number of PET scans, and the introduction of new devices for the imaging by manufacturers. The volume of PET procedures in the United States is approximately two million per year. Because of the increasing cases of chronic diseases and cancer in the United States. For instance, according to the National Cancer Institute, in 2020, over 1,806,590 new cancers and 606,520 cancer deaths were registered. In addition, as per the American Cancer Society, in 2021, nearly 1.9 million new diagnoses and 608,570 deaths were registered. Also, according to the CDC's prediction, by 2040, there will be 29.5 million cancer diagnoses. Furthermore, the presence of key market players that hold a major market share, such as Positron Corporation, Segami Corporation, Naviscan Inc, MedX Holdings Inc. and GE Healthcare, ensure the command of North America over the global market.

Competitive Landscape

The market's major key players are Some of the major manufacturers in the positron-emission tomography (PET) market are GE Healthcare, Philips Healthcare, Siemens Healthcare, Positron Corporation, Segami Corporation, Spectrum Dynamics Ltd., Naviscan Inc, MedX Holdings Inc., United Imaging, Neusoft Medical Systems, among others. The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the global positron-emission tomography (PET) market. For instance, on August 09, 2022, GE Healthcare collaborated with Nex Cubed to select six digital health start-ups for the inaugural Edison Accelerator in Canada. Also, on April 01, 2022, GE Healthcare inaugurated its new manufacturing plant in India.

GE Healthcare

Overview:

GE Healthcare is headquartered in Chicago, Illinois, United States, founded in 2004. It is a subsidiary of American Multinational Conglomerate General Electric. It is a leading manufacturer and distributor of diagnostic imaging and radiopharmaceuticals for imaging modalities used in medical imaging procedures.

Product Portfolio:

GE Healthcare's product portfolio for positron-emission tomography (PET) has Discovery IQ, Discovery MI Gen 2, MotionFree, NM 830, NM/CT 850, NM/CT 860, NM/CT 870 DR, NM/CT 870 CZT, Etc.

The global positron-emission tomography (PET) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Innovations and Developments
  - 4.1.1.2. Market Developments
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Proper Reimbursement Policies
  - 4.1.2.2. Lack of Skilled Professionals
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
- 7.1.2. Market Attractiveness Index, By Product Type Segment
7.2. Full-Ring PET Scanners
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Partial Ring PET Scanners

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
- 8.1.2. Market Attractiveness Index, By Application Segment
8.2. Cardiology
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Neurology
8.4. Oncology
8.5. Others

By End User

8.6. Introduction
- 8.6.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
- 8.6.2. Market Attractiveness Index, By End User Segment
8.7. Hospitals
- 8.7.1. Introduction
- 8.7.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.8. Diagnostic Centers
8.9. Academic & Research Centers
8.10. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. The U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. Australia
  - 9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking

11. Company Profiles

11.1. GE Healthcare
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Philips Healthcare
11.3. Siemens Healthcare
11.4. Positron Corporation
11.5. Segami Corporation
11.6. Spectrum Dynamics Ltd.
11.7. Naviscan Inc
11.8. MedX Holdings Inc.
11.9. United Imaging
11.10. Neusoft Medical Systems

LIST NOT EXHAUSTIVE